Acute Lymphoblastic Leukemia
New acute lymphoblastic leukemia findings from University of Heidelberg published
Published in Blood Weekly, June 19th, 2008
According to recent research from Mannheim, Germany, "Actual BCR-ABL kinase inhibition in vivo as determined by phospho-CRKL (pCRKL) monitoring has been recognized as a prognostic parameter in patients with chronic myelogenous leukemia treated with imatinib. We report a biomarker sub-study of the international phase I clinical trial of nilotinib (AMN107) using the established pCRKL assay in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia."
"A minimum dose (200 mg) required for effective BCR-ABL inhibition in imatinib resistant/intolerant leukemia was determined. The pre-clinical activity profile of nilotinib against mutant BCR-ABL was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-06-19)
More Articles from Blood Weekly
- McGill University Health Centre
Hip and knee replacement patients not receiving treatment to reduce blood clot risk - Research
Policy environments may shape international progress of human embryonic stem cell research - Alpha-thalassemia
New alpha-thalassemia findings from Mahidol University published - Angiotensins
Study data from M.A. Richardson et al provide new insights into angiotensins - Breast Cancer
Researchers from University of Indianapolis report recent findings in breast cancer - Cell Therapeutics, Inc.
Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan Zevalin Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
